Dosage & Administration

For subcutaneous use only. HERCEPTIN HYLECTA has different dosage and administration instructions than intravenous trastuzumab products.

Do not administer intravenously.

Do not substitute HERCEPTIN HYLECTA for or with ado-trastuzumab emtansine.

Perform HER2 testing using FDA-approved tests by laboratories with demonstrated proficiency.

The recommended dose of HERCEPTIN HYLECTA is 600 mg/10,000 units (600 mg trastuzumab and 10,000 units hyaluronidase) administered subcutaneously over approximately 2-5 minutes once every three weeks.

Get Your Patient on Herceptin Hylecta

See your patient's specific prior authorization requirements including coverage restrictions and step therapies
Or select your Insurance from the list below:

Herceptin Hylecta Prescribing Information

Herceptin Hylecta Prior Authorization Resources

Most recent state uniform prior authorization forms

Herceptin Hylecta PubMed™ News